Diagnosed Prevalent Cases of Systemic Sclerosis to Rise by 2030

Diagnosed prevalent cases of systemic sclerosis will reach 187,000 by 2030, forecasted by GlobalData

GlobalData, a leading data analytics company recently released a report, 'Systemic Sclerosis (SSc) – Epidemiology Forecast to 2030' that provided insights into the future status of diagnosed prevalent cases of systemic sclerosis.

The Seven Major Markets (7MM) include countries Canada, France, Germany, Italy, Japan, the United Kingdom, and the United States.

Scleroderma - CREST Syndrome - Signs - Symptoms - Diagnosis - Treatment - Prognosis
Scleroderma or CREST syndrome is a chronic, auto immune disease which manifests as thick, dry, fibrous skin. Scleroderma/CREST syndrome is classified as rheumatic and connective tissue disease.

‘Cases of Systemic sclerosis to rise by 2030. The United States will be having the high number of diagnosed prevalent cases of scleroderma in the 7MM at 114,000’

The key points from the report are,

• The cases of systemic sclerosis are expected to rise from 171,000 cases in 2020 to 187,000 in 2030, with an annual growth rate of 0.97%

• The United States will be having a high number of diagnosed prevalent cases of scleroderma in the 7MM at 114,000 while France will be the country with the lowest cases with nearly 6,000 cases

Stem Cell Transplant Improves Quality of Life of Patients With Severe Scleroderma
Patients with severe scleroderma who were treated with a stem cell transplant in a clinical trial showed improved survival and quality of life.

• Adults in the age group 50 years and above will be accountable for more than 75% whereas people between 18 and 39 will only contribute less than 10% of the total diagnosed prevalent cases

• Women to Men ratio for the cases is almost 5:1 as previously predicted by a majority of the studies

Breakthrough Mechanism That Causes Scleroderma Identified
Cells found in the lymphoid organs are activated and infiltrate the skin causing fibrosis and inflammation. These cells could be the target for treatment.

Bharti Prabhakar, MPH, Associate Project Manager at GlobalData, comments: “Management of SSc is mostly symptomatic and patients require regular clinical follow-up with early pulmonary function tests and echocardiography. The highly morbid and debilitating nature of SSc poses substantial socioeconomic consequences and significant productivity losses for patients.”

Source-Medindia

Shock-wave Therapy can Treat Finger Ulcers in Scleroderma Patients
Extracorporeal shock wave therapy can be good treatment option for scleroderma patients with finger ulcers